These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Long-Term Pharmacotherapy of Adults With Attention Deficit Hyperactivity Disorder: A Literature Review and Clinical Study. Fredriksen M; Peleikis DE Basic Clin Pharmacol Toxicol; 2016 Jan; 118(1):23-31. PubMed ID: 26404187 [TBL] [Abstract][Full Text] [Related]
25. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. Chan E; Fogler JM; Hammerness PG JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988 [TBL] [Abstract][Full Text] [Related]
26. Atomoxetine could improve intra-individual variability in drug-naïve adults with attention-deficit/hyperactivity disorder comparably with methylphenidate: A head-to-head randomized clinical trial. Ni HC; Hwang Gu SL; Lin HY; Lin YJ; Yang LK; Huang HC; Gau SS J Psychopharmacol; 2016 May; 30(5):459-67. PubMed ID: 26905919 [TBL] [Abstract][Full Text] [Related]
28. Prevalence, incidence and persistence of ADHD drug use in Japan. Okumura Y; Usami M; Okada T; Saito T; Negoro H; Tsujii N; Fujita J; Iida J Epidemiol Psychiatr Sci; 2019 Dec; 28(6):692-696. PubMed ID: 29804548 [No Abstract] [Full Text] [Related]
29. Updates on attention deficit hyperactivity disorder, child abuse and neglect, and sudden infant death syndrome. Daley KC Curr Opin Pediatr; 2003 Apr; 15(2):216-25. PubMed ID: 12640282 [No Abstract] [Full Text] [Related]
30. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders]. Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180 [TBL] [Abstract][Full Text] [Related]
31. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. Eiland LS; Bell EA; Erramouspe J Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313 [TBL] [Abstract][Full Text] [Related]
32. Extended-Release Mixed Amphetamine Salts vs Placebo for Comorbid Adult Attention-Deficit/Hyperactivity Disorder and Cocaine Use Disorder: A Randomized Clinical Trial. Levin FR; Mariani JJ; Specker S; Mooney M; Mahony A; Brooks DJ; Babb D; Bai Y; Eberly LE; Nunes EV; Grabowski J JAMA Psychiatry; 2015 Jun; 72(6):593-602. PubMed ID: 25887096 [TBL] [Abstract][Full Text] [Related]
33. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder. Perugi G; Vannucchi G Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896 [TBL] [Abstract][Full Text] [Related]
34. Update on adult attention-deficit/hyperactivity disorder. Hammerness P; Surman C; Miller K Curr Neurol Neurosci Rep; 2008 Nov; 8(6):484-9. PubMed ID: 18957185 [TBL] [Abstract][Full Text] [Related]
35. Cardiovascular safety of ADHD medications: rationale for and design of an investigator-initiated observational study. Hennessy S; Schelleman H; Daniel GW; Bilker WB; Kimmel SE; Guevara J; Cziraky MJ; Strom BL Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):934-41. PubMed ID: 20623519 [TBL] [Abstract][Full Text] [Related]
36. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Kollins SH Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709 [TBL] [Abstract][Full Text] [Related]
37. Attention-deficit-hyperactivity disorder: an update. Dopheide JA; Pliszka SR Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419 [TBL] [Abstract][Full Text] [Related]